Changes in dopamine agonist and antagonist activity following temporary inactivation of the neostraitum.
D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects; D002375:Catalepsy / Q000139:chemically induced; D002421:Caudate Nucleus; D002540:Cerebral Cortex / Q000502:physiology; D003342:Corpus Striatum / Q000187:drug effects*; D013181:Cortical Spreading Depression / Q000187:drug effects; D003913:Dextroamphetamine / Q000494:pharmacology; D004298:Dopamine / Q000502:physiology*; D018492:Dopamine Antagonists; D004569:Electroencephalography; D006801:Humans; D007267:Injections; D008297:Male; D011189:Potassium Chloride / Q000494:pharmacology; D011699:Putamen; D051381:Rats; D012965:Sodium Chloride / Q000494:pharmacology; D013238:Stereotaxic Techniques; D013239:Stereotyped Behavior / Q000187:drug effects; D013378:Substantia Nigra / Q000502:physiology; D013997:Time Factors; D014149:Tranquilizing Agents / Q000494:pharmacology
D000978:Antiparkinson Agents; D018492:Dopamine Antagonists; D014149:Tranquilizing Agents; D012965:Sodium Chloride; D011189:Potassium Chloride; D003913:Dextroamphetamine; D004298:Dopamine